DK2888251T3 - Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf - Google Patents
Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf Download PDFInfo
- Publication number
- DK2888251T3 DK2888251T3 DK13830653.5T DK13830653T DK2888251T3 DK 2888251 T3 DK2888251 T3 DK 2888251T3 DK 13830653 T DK13830653 T DK 13830653T DK 2888251 T3 DK2888251 T3 DK 2888251T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzen
- perfor
- inhibiting
- applications
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691652P | 2012-08-21 | 2012-08-21 | |
| PCT/AU2013/000925 WO2014028968A1 (en) | 2012-08-21 | 2013-08-21 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2888251T3 true DK2888251T3 (da) | 2019-07-29 |
Family
ID=50149277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13830653.5T DK2888251T3 (da) | 2012-08-21 | 2013-08-21 | Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9896443B2 (da) |
| EP (1) | EP2888251B1 (da) |
| AU (1) | AU2013305475B2 (da) |
| CA (1) | CA2881357C (da) |
| DK (1) | DK2888251T3 (da) |
| NZ (1) | NZ705096A (da) |
| WO (1) | WO2014028968A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| AU2014331938A1 (en) * | 2013-10-09 | 2016-04-28 | University Of Miami | Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation |
| BR112016014004B1 (pt) | 2013-12-19 | 2022-11-01 | Novartis Ag | Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
| CA3019380A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| KR102530512B1 (ko) | 2016-11-03 | 2023-05-08 | 브리스톨-마이어스 스큅 컴퍼니 | Romk 채널 억제제로서 유용한 치환된 비사이클 헤테로시클릭 유도체 |
| HUE052205T2 (hu) | 2016-12-09 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| WO2019113476A2 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
| EP4143219A2 (en) * | 2020-04-27 | 2023-03-08 | Vanderbilt University | Lymphocytes lacking perforin function |
| AU2022295990A1 (en) | 2021-06-18 | 2024-01-04 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP4644601B2 (ja) | 2003-10-24 | 2011-03-02 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| CA2558178A1 (en) | 2004-03-01 | 2005-09-09 | Peter Maccallum Cancer Institute | Recombinant perforin, expression and uses thereof |
| JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| WO2011075784A1 (en) | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Compounds, preparations and uses thereof |
-
2013
- 2013-08-21 AU AU2013305475A patent/AU2013305475B2/en active Active
- 2013-08-21 EP EP13830653.5A patent/EP2888251B1/en active Active
- 2013-08-21 US US14/422,498 patent/US9896443B2/en active Active
- 2013-08-21 WO PCT/AU2013/000925 patent/WO2014028968A1/en active Application Filing
- 2013-08-21 CA CA2881357A patent/CA2881357C/en active Active
- 2013-08-21 NZ NZ705096A patent/NZ705096A/en not_active IP Right Cessation
- 2013-08-21 DK DK13830653.5T patent/DK2888251T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2888251B1 (en) | 2019-04-24 |
| CA2881357C (en) | 2020-12-08 |
| AU2013305475B2 (en) | 2017-10-12 |
| US20150218150A1 (en) | 2015-08-06 |
| EP2888251A4 (en) | 2016-04-20 |
| EP2888251A1 (en) | 2015-07-01 |
| US9896443B2 (en) | 2018-02-20 |
| WO2014028968A1 (en) | 2014-02-27 |
| CA2881357A1 (en) | 2014-02-27 |
| NZ705096A (en) | 2018-02-23 |
| AU2013305475A1 (en) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2888251T3 (da) | Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf | |
| FIC20230011I1 (fi) | Farisimabi | |
| DK2841429T3 (da) | Tetrazolinonforbindelser og anvendelse deraf som pesticider | |
| DK3035936T3 (da) | Visse kemiske enheder, sammensætninger og fremgangsmåder | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| DK2863961T3 (da) | Hæmostatiske indretninger | |
| DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
| DK3293183T3 (da) | Hæmmerforbindelser | |
| UA24760S (uk) | Шрифт | |
| DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
| BR112014032488A2 (pt) | embalagem, e blanqueta | |
| DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
| DK2807160T3 (da) | Antifibrotiske forbindelser og anvendelser deraf | |
| BR112014027814A2 (pt) | agentes sinérgicos antimicrobianos. | |
| DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
| DK2877736T3 (da) | Skrue, skruedel og fremgangsmåde dertil | |
| BR112015007217A2 (pt) | compostos e usos do composto | |
| FR2986872B1 (fr) | . | |
| BR112014020372A8 (pt) | n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo | |
| DK2943460T3 (da) | 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf | |
| DK2805954T3 (da) | 7-substitueret hanfangichin b-derivat, og fremstillingsfremgangsmåde og anvendelse deraf | |
| DK2888100T3 (da) | Fremstillingsfremgangsmåde, fremstillingsform og anvendelse | |
| DOS2012000183S (es) | Enfriador | |
| BR112014032501A2 (pt) | composto, e, composição farmacêutica. | |
| DK3003298T3 (da) | Antifibrogene forbindelser, fremgangsmåder og anvendelser deraf |